Transcriptomic Plasticity of Human Alveolar Macrophages Revealed by Single-Cell RNA Sequencing Following Drug Exposure: Implications for Therapeutic Development
Authors:
- Penny L. GrovesPGPenny L. Groves
- Levi HockeyLHLevi Hockey
- Brendan J. O’sullivanBOBrendan J. O’sullivan
- Lai-Ying ZhangLZLai-Ying Zhang
- Zherui XiongZXZherui Xiong
- Quan H. NguyenQNQuan H. Nguyen
- Maxine E. TanMTMaxine E. Tan
- Viviana P. LutzkyVLViviana P. Lutzky
- Rohan A. DavisRDRohan A. Davis
- Daniel C. ChambersDCDaniel C. Chambers
- Simon H. ApteSimon H. Apte
Open Access
- 7 May 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 4439
Abstract
Alveolar macrophages (AM) must perform three seemingly opposing roles including homeostasis, driving inflammation, and facilitating tissue repair. Whilst there is now consensus (supported by a large body of human single cell RNA sequencing (scRNA-seq) data) that the cell subsets that perform these tasks can readily be found based on their transcriptome, their ontogeny has remained unclear. Moreover, there is agreement that in all types of pulmonary fibrosis (PF) there is an expanded population of profibrotic AM that may aberrantly drive PF. From a therapeutic viewpoint, there is great appeal in the notion that the transcriptional program in different AM subsets is not fixed but remains plastic and amenable to pharmacological reprogramming. Accordingly, this study addresses this question by performing scRNA-seq on human AM following treatment with drugs or perturbagens including pioglitazone, trametinib, nintedanib, lipopolysaccharide and the natural compound endiandrin A. Each treatment induced a unique global transcriptional change, driving the cells towards distinct subsets, further supported by trajectory analysis, confirming a high level of plasticity. Confirmatory experiments using qPCR demonstrated that single exposure to a compound induced a relatively stable transcriptome, whereas serial exposure to a different compound allowed the cells to be reprogrammed yet again to a different phenotype. These findings add new insight into the biology of AM and support the development of novel therapies to treat PF.Keywords
All Related Versions
Funding Information
- QLD Department of Health, Metro North Health SWIFT (SWIFT-142-2023, LE0668477, LE140100119, LE0237908)
- The Common Good (SWIFT-142-2023, LE0668477, LE140100119, LE0237908)
- an anonymous philanthropist (SWIFT-142-2023, LE0668477, LE140100119, LE0237908)
- UQ HDR Scholarship (SWIFT-142-2023, LE0668477, LE140100119, LE0237908)
- The Common Good top-up PhD Scholarship (SWIFT-142-2023, LE0668477, LE140100119, LE0237908)
- Australian Research Council (ARC) (SWIFT-142-2023, LE0668477, LE140100119, LE0237908)
This publication has 42 references indexed in Scilit:
- Exploring immune-related pathogenesis in lung injury: Providing new insights Into ALI/ARDSBiomedicine & Pharmacotherapy, 2024
- Therapeutic strategies targeting pro-fibrotic macrophages in interstitial lung diseaseBiochemical Pharmacology, 2023
- Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancerActa Pharmaceutica Sinica B, 2022
- Human alveolar macrophages do not rely on glucose metabolism upon activation by lipopolysaccharideBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2022
- SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosisCell, 2021
- Gene Set Knowledge Discovery with EnrichrCurrent Protocols, 2021
- Pulmonary alveolar proteinosis after lung transplantationRespirology Case Reports, 2020
- Pulmonary surfactant metabolism in the alveolar airspace: Biogenesis, extracellular conversions, recyclingAnnals of Anatomy - Anatomischer Anzeiger, 2017
- Mitochondrial Dysfunction Prevents Repolarization of Inflammatory MacrophagesCell Reports, 2016
- Particle-manufacturing technology-based inhalation therapy for pulmonary diseases2014